P
1.32
-0.01 (-0.75%)
| Previous Close | 1.33 |
| Open | 1.32 |
| Volume | 259,968 |
| Avg. Volume (3M) | 622,213 |
| Market Cap | 70,394,800 |
| Price / Book | 0.730 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2026 |
| Diluted EPS (TTM) | -1.18 |
| Total Debt/Equity (MRQ) | 0.69% |
| Current Ratio (MRQ) | 16.75 |
| Operating Cash Flow (TTM) | -53.36 M |
| Levered Free Cash Flow (TTM) | -47.35 M |
| Return on Assets (TTM) | -27.24% |
| Return on Equity (TTM) | -32.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | PMV Pharmaceuticals, Inc. | Mixed | Mixed |
AIStockmoo Score
-0.8
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.75 |
|
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.23% |
| % Held by Institutions | 73.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Euclidean Capital Llc | 31 Dec 2025 | 2,627,643 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |